PLASMA UNBOUND FREE FATTY ACIDS A DIAGNOSTIC FOR STROKE

描述(改编自申请人的摘要)： 这个应用程序的长期目标是开发一种简单的基于血液的分析方法 用于中风的早期诊断。尽管t-PA是一种有效的治疗方法 中风被采用的速度很慢，部分原因是它需要诊断 脑缺血损伤后3小时内进行CT扫描。尽管这个复杂的 在许多城市设施中都有技术，它的使用和 解释它的结果需要熟练的医生和技术人员， 紧急情况下可用。相比之下，我们提出的诊断方法， 血清游离游离脂肪酸(FFAu)的测定，包括一种简单、廉价、 几乎即时、易于访问的测量，具有高 有可能揭示缺血事件。在拟议的第一阶段研究中，我们 将确定用我们的ADIFAB荧光法测量的血浆FFAU水平 方法：提供大鼠脑缺血(卒中)的早期指标。 如果，正如我们从心肌缺血研究中预期的那样，血浆中的 FFAU在缺血损伤后几分钟内上升到非常高的水平， 然后我们应该能够使用大鼠模型来帮助定义特征 为在人类患者身上进行第二阶段试验做准备。 建议的商业应用： 如果成功，这项研究将证明游离脂肪酸(FFAu)提供了最早和最灵敏的基于血液分析的脑缺血测量方法。如果得到随后的II期和III期试验的支持，我们预计，与一种小型、廉价的单一用途荧光仪一起，这项检测将专门用于提供中风的最早迹象。该化验是基于我们的专利(美国..)该方法是仅报道的测定FFAU的方法，从而确保了相当大的商业应用。

DESCRIPTION(Adapted from applicant's abstract): The long term goal of this application is to develop a simple blood-based assay for the early diagnosis of stroke. Although t-PA is an effective treatment for stroke it has been slow to be adopted, in part because it requires a diagnostic CT scan within 3 hours of the ischemic insult. Although this sophisticated technology is available at many urban facilities, its use and the interpretation of its results requires skilled physicians and technicians, available on an emergency basis. In contrast, the diagnostic method we propose, the measurement of serum unbound FFA (FFAu), involves a simple, inexpensive, virtually instantaneous, and readily accessible measurement that has high potential for revealing the ischemic event. In the proposed Phase I studies we will determine if plasma FFAU levels, measured with our ADIFAB fluorescence method, provide an early indicator of cerebral ischemia (stroke) in the rat. If, as we expect from studies of myocardial ischemia, that plasma levels of FFAu rise to very high levels within minutes following the ischemic insult, then we should be able to use the rat model to help define the characteristics of this assay in preparation for a Phase II trial in human patients. PROPOSED COMMERCIAL APPLICATION: If successful this research would demonstrate that unbound free fatty acids (FFAu) provide the earliest and most sensitive blood-assay based measure of cerebral ischemia. If supported by subsequent phase II and III trials, we would expect that, in conjunction with a small, inexpensive single purpose fluorometer, that this assay would be used exclusively to provide the earliest indication of stroke. This assay is based on our patented (US..) method which is only reported method for measuring FFAu, thereby ensuring considerable commercial application.